MedPath

Alginic acid

Generic Name
Alginic acid
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
9005-32-7
Unique Ingredient Identifier
8C3Z4148WZ
Background

Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (Phacophycae) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages . Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years . Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer . It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid . Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years .

Indication

Indicated for the management of gastric reflux, reflux oesophagitis, hiatus hernia, heartburn (including heartburn of pregnancy) and similar gastric distress .

Associated Conditions
Dyspepsia, Flatulence, Gastro-esophageal Reflux Disease (GERD), Gastroesophageal Reflux, Heartburn, Reflux Acid, Reflux Esophagitis (RE), Regurgitation
Associated Therapies
-
finance.yahoo.com
·

Norgine submits Marketing Authorisation Application to the EMA for Eflornithine in High-Risk Neuroblastoma

Norgine filed a marketing authorisation application with the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA for HRNB, showed improved survival rates. Norgine aims to provide new treatment options for pediatric oncology patients.
finance.yahoo.com
·

Norgine submits Marketing Authorisation Application to the EMA for eflornithine in high-risk neuroblastoma

Norgine filed a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA as the first oral maintenance therapy for HRNB, shows improved survival rates. Norgine aims to provide new treatment options for HRNB patients.
stocktitan.net
·

Fennec Pharmaceuticals Inc. Latest Stock News & Market Updates

Fennec Pharmaceuticals (FENC) is a commercial-stage biopharmaceutical company dedicated to developing cancer therapies, with a focus on pediatric oncology. Its lead product, PEDMARK, is a sodium thiosulfate formulation approved by the FDA to prevent cisplatin-induced hearing loss in pediatric patients. Recent developments include a licensing agreement with Norgine for PEDMARQSI commercialization in Europe, Australia, and New Zealand, and EU marketing authorization for PEDMARQSI.

Shield Therapeutics announces promising paediatric trial results.

Shield Therapeutics' FORTIS/ST10-01-305 trial showed significant efficacy, safety, and tolerability of its oral liquid suspension, leading to planned regulatory submissions to the US FDA and EMA for a paediatric indication in 2025. The study met all primary endpoints, demonstrating clinically relevant Hb level increases, with no treatment-related adverse events in the ferric maltol group. Shield expects to receive €1m development milestones from Norgine upon EMA approval.
© Copyright 2025. All Rights Reserved by MedPath